Please Wait
Applying Filters...
menu
    • menu
    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Zoliflodacin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 23,569Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Entasis Therap’s Nuzolvence Receives Approval in US
    Entasis Therap’s Nuzolvence Receives Approval in US

    12 Dec 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219491

    FDA
    12 Dec 2025
    Share Share
    FDA Approves Nuzolvence for Uncomplicated Urogenital Gonorrhea
    FDA Approves Nuzolvence for Uncomplicated Urogenital Gonorrhea

    12 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251212683585/en/U.S.-FDA-Approves-NUZOLVENCE-zoliflodacin-a-First-in-Class-Single-dose-Oral-Antibiotic-for-the-Treatment-of-Uncomplicated-Urogenital-Gonorrhea-in-Adults-and-Adolescents

    BUSINESSWIRE
    12 Dec 2025
    Share Share
    Innoviva Specialty Therapeutics Presents Zoliflodacin Phase 3
    Innoviva Specialty Therapeutics Presents Zoliflodacin Phase 3

    20 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-20/innoviva-specialty-therapeutics-announces-oral-presentation-featuring-new-analyses-from-the-zoliflod

    PHARMIWEB
    20 Oct 2025
    Share Share
    Innoviva To Deliver Six ID & Critical Care Talks At IDWeek 2025
    Innoviva To Deliver Six ID & Critical Care Talks At IDWeek 2025

    07 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-07/innoviva-specialty-therapeutics-to-deliver-six-presentations-from-its-infectious-diseases-and-critic

    PHARMIWEB
    07 Oct 2025
    Share Share
    FDA Grants Priority Review for Zoliflodacin NDA for Gonorrhea
    FDA Grants Priority Review for Zoliflodacin NDA for Gonorrhea

    12 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250612432209/en/FDA-Grants-Priority-Review-for-Zoliflodacin-New-Drug-Application-for-the-Treatment-of-Uncomplicated-Gonorrhea-and-Assigns-Target-PDUFA-Date-of-December-15-2025

    BUSINESSWIRE
    12 Jun 2025
    Share Share
    Innoviva Specialty Therapeutics: FDA Accepts Zoliflodacin NDA
    Innoviva Specialty Therapeutics: FDA Accepts Zoliflodacin NDA

    10 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250610102070/en/Innoviva-Specialty-Therapeutics-Receives-FDA-New-Drug-Application-Acceptance-for-Zoliflodacin-a-First-in-Class-Oral-Antibiotic-for-Uncomplicated-Gonorrhea-in-Adults

    BUSINESSWIRE
    10 Jun 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.